<DOC>
	<DOCNO>NCT00555594</DOCNO>
	<brief_summary>To determine effect subconjunctival Bevacizumab corneal neovascularization</brief_summary>
	<brief_title>Prospective Study Determine Effect Subconjunctival Bevacizumab ( AVASTIN ) Corneal Neovascularization</brief_title>
	<detailed_description>Corneal transplantation commonly perform transplant surgery world today . Immunologic rejection lead cause graft failure , 25 % graft recipient experience least one episode rejection . Of episode , 20 % irreversible . The rate corneal graft rejection high-risk eye , corneal neovascularization , report 50 % 70 % . Vascularized corneas much high rate graft rejection avascular cornea . Whereas normal cornea devoid blood lymphatic vessel , invade cornea secondary variety corneal diseases surgery . This reduce visual acuity , also render cornea high-risk , subsequent corneal transplantation performed.Anti-angiogenesis , pharmacologic inhibition new blood vessel growth formation , new treatment strategy active vigorous investigation . Multiple growth factor show contribute molecular event involve regulation blood vessel growth Similarly , assume angiogenic growth factor vascular endothelial growth factor ( VEGF ) , consider major pro-angiogenic factor , could play role pathogenesis neovascularization . Several approach take neutralize VEGF . Bevacizumab ( Avastin ) full-length humanize murine monoclonal antibody VEGF molecule.It bind inhibits biologic activity human VEGF prevent interaction molecule receptor surface endothelial cell . The interaction VEGF receptor lead endothelial cell proliferation new vessel formation . There evidence triamcinolone acetonide ( TA ) inhibit vasogenic edema inflammation , decrease vascular leakage , reduce secretion VEGF pigment epithelial cell oxidative stress , down-regulates expression VEGF gene vascular smooth muscle cell Furthermore , TA decrease paracellular permeability culture epithelial cell down-regulates inflammatory expression endothelial adhesion molecule .</detailed_description>
	<mesh_term>Neovascularization , Pathologic</mesh_term>
	<mesh_term>Corneal Neovascularization</mesh_term>
	<mesh_term>Bevacizumab</mesh_term>
	<criteria>1 . Presence vessel minimum one quadrant 2. vessel penetrate 0.5 mm limb , depth 3. sign inform consent 4. could attend frequent ophthalmologic revision treatment could wait 6 month surgical procedure . 1 . Patients urgent need penetrate keratoplasty , pregnancy lactancy 2 . Patient may need additional procedure penetrate keratoplasty .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>November 2007</verification_date>
	<keyword>corneal neovascularization</keyword>
	<keyword>Bevacizumab ( Avastin )</keyword>
	<keyword>Immunologic rejection</keyword>
	<keyword>vascular endothelial growth factor</keyword>
</DOC>